RecruitingPhase 1NCT07646106

THE-0504 in Patients With Solid Tumors

NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors

Sponsor

Thena Biotech S.r.l.

Enrollment

30 participants

Start Date

Nov 13, 2024

Study Type

INTERVENTIONAL

Conditions

Triple-Negative Breast Cancer Gastric Cancer (GC)Small Cell Lung Cancer ( SCLC )Pancreas Adenocarcinoma Colorectal Carcinoma (CRC)

Summary

Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called THE-0504 for people with colorectal carcinoma (crc), gastric cancer (gc), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTHE-0504

THE-0504 will be administered intravenously according to the treatment regimen specified in the protocol.

Locations(1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07646106

Related Trials

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

NCT072976672 locations

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374306 locations

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT073405414 locations

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

NCT0608124442 locations

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT0346097782 locations